Cubist Systematic Strategies’s PDL BioPharma, Inc. PDLI Stock Holding History

Cubist Systematic Strategies’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-35,935	Closed	-$117K	–	2657
2019 Q4	$117K	Buy	+35,935	New	+$104K	﹤0.01%	2162
2017 Q4	–	Sell	-49,062	Closed	-$166K	–	2249
2017 Q3	$166K	Buy	49,062 +19,144	+64%	+$53.2K	0.01%	1512
2017 Q2	$74K	Buy	29,918 +12,665	+73%	+$29.1K	﹤0.01%	1497
2017 Q1	$39K	Sell	17,253 -35,798	-67%	-$79.2K	﹤0.01%	1501
2016 Q4	$112K	Buy	53,051 +28,280	+114%	+$78.9K	0.01%	1453
2016 Q3	$83K	Sell	24,771 -7,539	-23%	-$23.9K	0.01%	1510
2016 Q2	$101K	Buy	32,310 +9,794	+43%	+$32.7K	0.01%	1502
2016 Q1	$75K	Sell	22,516 -929	-4%	-$2.9K	﹤0.01%	1439
2015 Q4	$83K	Buy	23,445 +2,233	+11%	+$9.35K	﹤0.01%	1537
2015 Q3	$107K	Buy	+21,212	New	+$122K	0.01%	1618

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

ECM

Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cubist Systematic Strategies's PDLI Position: Q1 2020 in Review

Cubist Systematic Strategies sold out of PDL BioPharma, Inc. (PDLI) in Q1 2020, closing a stake of 35,935 shares — an estimated $117K sold.

Cubist Systematic Strategies first reported a position in PDLI in Q3 2015 and held it in 10 quarters. The position peaked at $166K in Q3 2017. 132 funds tracked by Wall St. Rank hold PDLI as of Q1 2020.

Cubist Systematic Strategies reported no remaining PDL BioPharma, Inc. position as of Q1 2020 after selling out during the quarter.
Cubist Systematic Strategies sold 35,935 PDL BioPharma, Inc. shares in Q1 2020, an estimated $117K.
Cubist Systematic Strategies first reported a position in PDL BioPharma, Inc. in Q3 2015 and held it in 10 quarters.
Cubist Systematic Strategies's PDL BioPharma, Inc. position peaked at $166K in Q3 2017.
132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2020.

Based on Cubist Systematic Strategies's 13F filing for Q1 2020, filed 15 May 2020.